BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster.  BIAL Biotech is a wholly owned subsidiary of BIAL.

We are dedicated to innovative, research and development in the field of neurodegeneration.

Our lead program builds on the genetic association between Parkinson’s disease (PD) and the GBA1 gene. BIAL Biotech team has extensive experience in drug discovery and development, focused on genetic and neurodegenerative diseases. Our team is highly motivated to make a real difference as soon as possible for patients with severe neurodegenerative and neurodevelopmental disease.

Management Team

Kees Been

Kees Been was formerly the President and CEO of EnVivo Pharmaceuticals; He led EnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.

Dana C. Hilt, MD

Dana Hilt has more than 22 years of drug development experience, primarily of CNS drugs. Most recently, he served as Senior Vice President, clinical development and Chief Medical Officer at FORUM Pharmaceuticals, where he was involved in the development of Encenicline, an alpha-7 agonist for the treatment of cognitive impairment in Schizophrenia and Alzheimer’s disease. Prior to joining FORUM, Dana held positions at various pharmaceutical companies, including Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. During this time, he was involved in the development of a variety of potential therapeutics for Parkinson’s disease, ALS, Alzheimer’s disease, oncologic diseases including malignant glioma, chronic pain, metabolic disorders, and inflammatory conditions. Prior to that, he established a Clinical Neuroscience Group at Amgen and was a faculty member at the University of Maryland School of Medicine. Dana also previously served on the staff of the NIH for five years, and has co-authored more than 100 publications and book chapters in basic and clinical neuroscience. Dana earned his M.D. from Tufts University School of Medicine in Boston and trained in Internal Medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital.

Peter Lansbury, PhD

Peter Lansbury manages the company’s research activities. He also retains his position as a professor of neurology at Harvard Medical School. Previously, Peter was Founder and Chief Scientific Officer of Link Medicine until it was acquired by AstraZeneca in 2012. Peter served as a Director of the Morris K. Udall Research Center of Excellence in Parkinson's Disease at Brigham and Women's Hospital. Peter received his doctorate from Harvard University, where he worked for Nobel laureate E. J. Corey.